IL6 and Hyperkalemia: Ramipril significantly reduced markers of endothelial dysfunction (-79.6%) and inflammation (hs-CRP -46.5%, IL-6 -27.1%, TNF-α -51.7%, all p < 0.001). Ramipril lowered systolic and diastolic BP significantly more than placebo. No severe hyperkalemia or serious adverse events were reported.